WEBULL
WebtradeDownload

Shandong Weigao Group Medical Polymer (SEHK:1066) Reported Mixed Half Year Results, Is The Valuation Gap Enough?

Simply Wall St · 1d ago

Why Shandong Weigao Group Medical Polymer’s latest earnings and dividend move matter

Shandong Weigao Group Medical Polymer (SEHK:1066) drew investor attention after half year 2026 results showed higher sales but lower profit, alongside a proposed reduced interim dividend that affects near term income expectations.

At a share price of HK$3.265, Shandong Weigao Group Medical Polymer has seen short term pressure, with a 30 day share price return down 5.09%, and longer term sentiment has weakened further with a 1 year total shareholder return down 40.24%.

The small 1 day share price gain of 1.56% around the earnings and dividend announcement suggests investors are weighing the higher sales against lower net income and the reduced interim dividend, which can shift views on both growth prospects and income support.

Compare how Shandong Weigao Group Medical Polymer stacks up on income resilience by scanning our hand picked 421 dividend fortresses that aim to balance yield with balance sheet strength.

Bulls will point to Shandong Weigao Group Medical Polymer’s revenue growth and discounted price tags, while bears focus on profit pressure and a lower interim dividend. Which side does the current valuation evidence support next?

Price to earnings of 9.2x for Shandong Weigao Group Medical Polymer: Is it justified?

On valuation, Shandong Weigao Group Medical Polymer trades on a P/E of 9.2x while its share price is HK$3.265, and multiple checks flag this as low compared with both peers and the wider Hong Kong medical equipment industry.

The P/E ratio compares the company’s current share price with its earnings per share and is a simple way to see how much investors are paying for current profits. For Shandong Weigao Group Medical Polymer, current earnings are assessed as high quality and analysts expect earnings to grow 12.14% per year, so a low P/E suggests the market is not assigning a high price to those forecast profits.

Relative measures reinforce that point. The company’s 9.2x P/E is below the peer average of 20.1x and below the Hong Kong Medical Equipment industry average of 17.6x. The estimated fair P/E of 13.8x also sits well above the current level. That is a sizeable valuation gap that some investors may view as potential room for the market to move closer to the fair ratio over time.

Explore the SWS fair ratio for Shandong Weigao Group Medical Polymer.

Result: Price-to-earnings of 9.2x (UNDERVALUED)

However, Shandong Weigao Group Medical Polymer still faces risks if profit growth slows again or if weaker shareholder returns keep pressure on the share price.

Find out about the key risks to this Shandong Weigao Group Medical Polymer narrative.

Another view on Shandong Weigao Group Medical Polymer’s value

The SWS DCF model also points to Shandong Weigao Group Medical Polymer trading below estimated value. The current share price of HK$3.27 is compared with a DCF fair value of HK$8.78, which again frames the stock as undervalued. The key question is which signal investors should place more weight on for the long term.

Look into how the SWS DCF model arrives at its fair value.

1066 Discounted Cash Flow as at Sep 2026
1066 Discounted Cash Flow as at Sep 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shandong Weigao Group Medical Polymer for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 258 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of risks and rewards surrounding Shandong Weigao Group Medical Polymer can appear finely balanced, so it is helpful to review the details yourself and act promptly while sentiment remains in flux, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Shandong Weigao Group Medical Polymer?

If Shandong Weigao Group Medical Polymer has caught your eye, now is a good time to broaden your watchlist with other clear, data driven ideas before the market moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.